Description: AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
Home Page: www.astrazeneca.com
AZN Technical Analysis
1 Francis Crick Avenue
Cambridge,
CB2 0AA
United Kingdom
Phone:
44 20 3749 5000
Officers
| Name | Title |
|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director |
| Dr. Aradhana Sarin M.D. | CFO & Exec. Director |
| Mr. Marc Dunoyer | CEO of Alexion & Chief Strategy Officer |
| Ms. Pam P. Cheng | EVP of Operations & Information Technology and Member of External Sustainability Advisory Board |
| Mr. Chris Sheldon | Head of Investor Relations |
| Mr. Jeffrey Pott | Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board |
| Ms. Katarina Ageborg | EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board |
| Gonzalo Vina | Head of Global Media Relations |
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 18.4162 |
|---|---|
| Trailing PE: | 110.2846 |
| Price-to-Book MRQ: | 6.2133 |
| Price-to-Sales TTM: | 4.6505 |
| IPO Date: | 1993-05-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 83100 |